Successful Approval of Liru Ping® Injection by Huadong Medicine: Bringing New Hope for Obesity or Overweight Patients

Huadong Medicine recently announced that its wholly-owned subsidiary, Sino-American Huadong, has received the "Drug Registration Certificate" issued by the National Medical Products Administration (NMPA) for the application of market approval of Liru Ping® injection for the indications of obesity or overweight. This great news brings new hope for patients struggling with obesity or overweight.

Liru Ping® injection is a glucagon-like peptide-1 (GLP-1) receptor agonist, known for its effects in weight reduction, blood sugar control, and cardiovascular benefits. Obesity and overweight have become significant health concerns in modern society, causing numerous negative impacts on individuals' lives and health. The approval of Liru Ping® provides a new treatment option for these patients.

Liru Ping® injection works by activating GLP-1 receptors, improving insulin secretion and gastrointestinal motility, thereby reducing appetite, delaying gastric emptying, and promoting insulin release to assist patients in weight loss. Additionally, Liru Ping® also helps lower blood sugar levels, making it a win-win treatment for obese or overweight patients with diabetes. Furthermore, Liru Ping® has shown protective effects on the cardiovascular system, which is particularly advantageous for patients with a higher risk of cardiovascular diseases.

The market approval of Liru Ping® injection represents the progress in medical technology and the result of Huadong Medicine's commitment to innovative drug development. As a patient-oriented company, Huadong Medicine continuously introduces efficient and safe medications, making significant contributions to the field of human health.

Liru Ping® injection is available in two specifications: 3ml:18mg (pre-filled injection pen) and 3ml:18mg (cartridge). This design not only facilitates patient usage but also enhances the accuracy and safety of medication.

It is important to note that Liru Ping® injection is a prescription drug and should be used under the guidance of a doctor. Patients should closely monitor their physical condition and potential side effects of the medication. However, with the continuous advancement of medical science and the market approval of Liru Ping® injection, we can provide more effective treatment options for obese or overweight patients, helping them regain health and confidence.

The success of Huadong Medicine not only affirms the company's strength and innovation capabilities but also inspires the entire pharmaceutical industry. We believe that through continuous efforts and innovation, we can bring hope to more patients and contribute more to the cause of human health.

Let us look forward to the market availability of Liru Ping® injection, bringing new treatment options for obese or overweight patients and contributing to the development of the healthcare industry.